Thinly traded nano cap Synlogic (NASDAQ:SYBX) is up 6% premarket on increased volume in response to its announcement of positive results from a bridging study evaluating a solid formulation of SYNB1618 in healthy volunteers.
It says the safety and tolerability data support continued development for the potential treatment of phenylketonuria (PKU). A Phase 2 study should launch in H1 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.